KR100196060B1 - 흡입 투여를 위한 타우린-기저 제약 조성물 - Google Patents
흡입 투여를 위한 타우린-기저 제약 조성물 Download PDFInfo
- Publication number
- KR100196060B1 KR100196060B1 KR1019920702994A KR920702994A KR100196060B1 KR 100196060 B1 KR100196060 B1 KR 100196060B1 KR 1019920702994 A KR1019920702994 A KR 1019920702994A KR 920702994 A KR920702994 A KR 920702994A KR 100196060 B1 KR100196060 B1 KR 100196060B1
- Authority
- KR
- South Korea
- Prior art keywords
- taurine
- hypotaurine
- inhalation
- asthma
- aerosol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 69
- 229960003080 taurine Drugs 0.000 claims abstract description 35
- 239000000443 aerosol Substances 0.000 claims abstract description 16
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 claims abstract description 15
- 208000006673 asthma Diseases 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 5
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000003380 propellant Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 238000003915 air pollution Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- 229940123457 Free radical scavenger Drugs 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000013125 spirometry Methods 0.000 description 2
- -1 taurine amides Chemical class 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- OJFAFAAQEAAQJU-UHFFFAOYSA-N 2-aminoethanesulfinic acid;2-aminoethanesulfonic acid Chemical compound NCCS(O)=O.NCCS(O)(=O)=O OJFAFAAQEAAQJU-UHFFFAOYSA-N 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 231100000037 inhalation toxicity test Toxicity 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR91/03693 | 1991-03-27 | ||
| FR91/3693 | 1991-03-27 | ||
| FR9103693A FR2674434B1 (fr) | 1991-03-27 | 1991-03-27 | Nouvelle composition pharmaceutique a base de taurine pour l'administration par inhalation. |
| PCT/FR1992/000282 WO1992017170A1 (fr) | 1991-03-27 | 1992-03-27 | Nouvelle composition pharmaceutique a base de taurine pour l'administration par inhalation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR930700088A KR930700088A (ko) | 1993-03-13 |
| KR100196060B1 true KR100196060B1 (ko) | 1999-06-15 |
Family
ID=9411170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019920702994A Expired - Fee Related KR100196060B1 (ko) | 1991-03-27 | 1992-03-27 | 흡입 투여를 위한 타우린-기저 제약 조성물 |
Country Status (14)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100368011B1 (ko) * | 2000-03-23 | 2003-01-14 | 조금호 | 타우린을 함유하는 경장유동액 |
| KR20100075435A (ko) * | 2007-08-27 | 2010-07-02 | 비톱 에이지 | 알레르기성 또는 바이러스성 호흡기 질환 치료용 오스모라이트 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2696080B1 (fr) * | 1992-09-30 | 1994-12-23 | Jesus Covarrubias | Filtre à cigarette pour l'administration de taurine par inhalation. |
| KR100396362B1 (ko) * | 1999-07-02 | 2003-09-02 | 가부시키가이샤 닛뽕 가가꾸 고오교쇼 | 아미노에탄술폰산 함유 제제 |
| FR2833840B1 (fr) * | 2001-12-21 | 2010-06-18 | Rytek | Methodes et compositions pour le traitement de pathologies respiratoires |
| FR2833839A1 (fr) * | 2001-12-21 | 2003-06-27 | Rytek | Methodes et compositions pour le traitement de pathologies respiratoires |
| FR2879100B1 (fr) | 2004-12-09 | 2007-07-06 | Lionel Bueno | Compositions pour le traitement des pathologies oculaires de surface et de la retine |
| DE102008039231A1 (de) | 2008-08-22 | 2010-02-25 | Bitop Ag | Verwendung von Glucosylglycerol |
| GB201305813D0 (en) * | 2013-03-28 | 2013-05-15 | Vectura Ltd | Compositions and methods |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1226897B (it) * | 1987-09-18 | 1991-02-21 | Richerche Di Schiena Snc Del D | Derivato di taurina, sua preparazione e composizioni farmaceutiche relative |
| JPH0368549A (ja) * | 1989-08-07 | 1991-03-25 | Yamanouchi Pharmaceut Co Ltd | タウリン誘導体及びこれを有効成分とするロイコトリエン拮抗剤 |
-
1991
- 1991-03-27 FR FR9103693A patent/FR2674434B1/fr not_active Expired - Fee Related
-
1992
- 1992-03-27 CA CA002083825A patent/CA2083825A1/fr not_active Abandoned
- 1992-03-27 DK DK92909536.2T patent/DK0533896T3/da active
- 1992-03-27 EP EP92909536A patent/EP0533896B1/fr not_active Expired - Lifetime
- 1992-03-27 DE DE69213874T patent/DE69213874T2/de not_active Expired - Fee Related
- 1992-03-27 WO PCT/FR1992/000282 patent/WO1992017170A1/fr active IP Right Grant
- 1992-03-27 ES ES92909536T patent/ES2093829T3/es not_active Expired - Lifetime
- 1992-03-27 BR BR9204815A patent/BR9204815A/pt not_active Application Discontinuation
- 1992-03-27 JP JP4508593A patent/JPH06501954A/ja active Pending
- 1992-03-27 KR KR1019920702994A patent/KR100196060B1/ko not_active Expired - Fee Related
- 1992-03-27 AT AT92909536T patent/ATE142874T1/de active
- 1992-03-27 AU AU16659/92A patent/AU656775B2/en not_active Ceased
- 1992-11-26 NO NO924578A patent/NO301521B1/no unknown
-
1996
- 1996-12-18 GR GR960403529T patent/GR3022083T3/el unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100368011B1 (ko) * | 2000-03-23 | 2003-01-14 | 조금호 | 타우린을 함유하는 경장유동액 |
| KR20100075435A (ko) * | 2007-08-27 | 2010-07-02 | 비톱 에이지 | 알레르기성 또는 바이러스성 호흡기 질환 치료용 오스모라이트 |
| KR101638637B1 (ko) | 2007-08-27 | 2016-07-11 | 비톱 에이지 | 알레르기성 또는 바이러스성 호흡기 질환 치료용 오스모라이트 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0533896A1 (fr) | 1993-03-31 |
| JPH06501954A (ja) | 1994-03-03 |
| ES2093829T3 (es) | 1997-01-01 |
| AU1665992A (en) | 1992-11-02 |
| CA2083825A1 (fr) | 1992-09-28 |
| GR3022083T3 (en) | 1997-03-31 |
| EP0533896B1 (fr) | 1996-09-18 |
| BR9204815A (pt) | 1993-07-27 |
| FR2674434B1 (fr) | 1993-06-18 |
| WO1992017170A1 (fr) | 1992-10-15 |
| AU656775B2 (en) | 1995-02-16 |
| ATE142874T1 (de) | 1996-10-15 |
| DE69213874D1 (de) | 1996-10-24 |
| NO301521B1 (no) | 1997-11-10 |
| NO924578L (no) | 1992-11-26 |
| DK0533896T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1997-02-17 |
| DE69213874T2 (de) | 1997-04-03 |
| FR2674434A1 (fr) | 1992-10-02 |
| KR930700088A (ko) | 1993-03-13 |
| NO924578D0 (no) | 1992-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100414699B1 (ko) | 폐병치료에유용한디뉴클레오티드 | |
| KR100910888B1 (ko) | 에어로졸화 이송을 위한 적절한 토브라마이싱의 조성물 | |
| EP0502054B1 (en) | An aerosol preparation of glutathione and a method for augmenting glutathione level in lungs | |
| JP2774379B2 (ja) | 医薬エアロゾール組成物ならびにそれらのウイルス疾患の治療および予防用途 | |
| KR100196060B1 (ko) | 흡입 투여를 위한 타우린-기저 제약 조성물 | |
| WO2015014209A1 (zh) | 稳定渗透压的丙酮酸药物组成及其在健康人和肺病病人中的排毒作用 | |
| HOFMANN et al. | Aerosolized amiloride: dose effect on nasal bioelectric properties, pharmacokinetics, and effect on sputum expectoration in patients with cystic fibrosis | |
| WO2022046668A1 (en) | Compositions and methods for reducing the transmissivity of illnesses | |
| US4689213A (en) | Method and composition for treating bronchospastic airway diseases | |
| KR880003973A (ko) | 약리적 활성 화합물 및 용도 | |
| TWI818601B (zh) | 用於上呼吸道給藥之組成物及其用途 | |
| JP2003513048A (ja) | 気道狭窄の治療のための酸化窒素の使用 | |
| CN110870855A (zh) | 一种吸入用乙酰半胱氨酸溶液制剂及其制备方法 | |
| US20030105162A1 (en) | Method for treating bronchial constriction and bronchospasm | |
| RU2190422C1 (ru) | Аэрозоль для ингаляций фармацевтической композиции глутовент и способ лечения с его использованием | |
| EP4247350A1 (en) | Composition for use in a method for the prevention and treatment of diseases of the respiratory system | |
| RU2217159C1 (ru) | Раствор для ингаляций фармацевтической композиции глутовент и способ его терапевтического применения | |
| WO2025167739A1 (zh) | 化合物在制备预防和/或治疗高原病的药物中的应用 | |
| DK202170549A1 (en) | Medicament for inhalation or breathing, and inhaler or breathing device comprising same | |
| WO2003086429A1 (en) | A pharmaceutical formulation for endonasal administration and its use in the treatment of rhinitic symptoms | |
| EA023654B1 (ru) | Полимерный полисахарид из семян тамариндового дерева для применения в лечении сухого кашля | |
| WO2022091067A1 (en) | Composition for use in the prevention and treatment of diseases of the respiratory system | |
| CN118056568A (zh) | 用于抗病毒或氧化预处理的组合物及其制备和使用方法 | |
| Uthus | United States Department of Agriculture, Agricultural Research Service, Grand Forks Human Nutrition Research Center, Grand Forks, ND 58202 | |
| HOFMANN et al. | Bioelectric Properties, Pharmacokinetics, and Effect on Sputum Expectoration in Patients with Cystic Fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19921127 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19970325 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19921127 Comment text: Patent Application |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 19981127 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 19990218 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 19990219 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20021105 |